Product Overview
Aleglitazar | T14176 | TargetMol Chemicals
CAS: 475479-34-6
Smiles: CO[C@@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)c2ccsc12)C(O)=O
Formula: C24H23NO5S
Pathway: DNA Damage/DNA Repair|||Metabolism
Target: PPAR
Receptor: N/A
Bioactivity: Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM. IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ) Target: PPARα/γ Aleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM.
Molecular Weight: 437, 51